Glonghui April 25 | NORDNORD (NVO.US) US stocks fell 1.1% to $124.74 before the market. According to the news, US Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders said on Wednesday that the committee is investigating Novo Nordisk's pricing. In a letter sent to Novo Nordisk's CEO on Wednesday, Sanders asked Novo Nordisk to provide “internal communication on the pricing of this drug in the US” and explained why Ozempic and Wegovy have the same ingredients (both simeglutide), but Wegovy's pricing is clearly a bit more expensive. Sanders stressed that the price of GLP-1 drugs “must be lowered” so that consumers can buy them, and at the same time, the government does not go bankrupt because of reimbursing these drugs.
美股异动｜诺德诺德盘前跌1.1% 美国参议院正对诺和诺德GLP-1药物定价展开调查
Changes in US stocks | NORDNORD fell 1.1% before the market, the US Senate is investigating the pricing of Novo Nordisk GLP-1 drugs
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.